Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review
Abstract
:1. Introduction
2. Materials and Methods
2.1. Search Method
2.2. Study Selection
2.3. Data Extraction
3. Results
3.1. Studies’ Characteristics
3.2. Disease-Free Survival Analysis
3.3. Overall Survival Analysis
3.4. Recurrence Patterns
3.5. Complication Rate
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Jhingran, A.; Burke, T.W.; Eifel, P.J. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int. J. Radiat. Oncol. Biol. Phys. 2003, 56, 1366–1372. [Google Scholar] [CrossRef] [PubMed]
- Colombo, N.; Creutzberg, C.; Amant, F.; Bosse, T.; González-Martín, A.; Ledermann, J.; Marth, C.; Nout, R.; Querleu, D.; Mirza, M.R.; et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, treatment and follow-up. Ann. Oncol. 2016, 27, 16–41, Correction in Ann. Oncol. 2017, 28 (Suppl. S4), iv167–iv168. [Google Scholar] [CrossRef] [PubMed]
- Nout, R.A.; Smit, V.T.; Putter, H.; Jürgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.; van der Steen-Banasik, E.; Mens, J.; Slot, A.; Kroese, M.S.; et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomised trial. Lancet 2010, 375, 816–823. [Google Scholar] [CrossRef]
- SGO Clinical Practice Endometrial Cancer Working Group; Burke, W.M.; Orr, J.; Leitao, M.; Salom, E.; Gehrig, P.; Olawaiye, A.B.; Brewer, M.; Boruta, D.; Herzog, T.J.; et al. Endometrial cancer: A review and current management strategies: Part II. Gynecol. Oncol. 2014, 134, 393–402. [Google Scholar] [CrossRef] [PubMed]
- Pai, H.H.; Souhami, L.; Clark, B.G.; Roman, T. Isolated Vaginal Recurrences in Endometrial Carcinoma: Treatment Results Using High-Dose-Rate Intracavitary Brachytherapy and External Beam Radiotherapy. Gynecol. Oncol. 1997, 66, 300–307. [Google Scholar] [CrossRef]
- Legge, F.; Restaino, S.; Leone, L.; Carone, V.; Ronsini, C.; Di Fiore, G.L.M.; Pasciuto, T.; Pelligra, S.; Ciccarone, F.; Scambia, G.; et al. Clinical outcome of recurrent endometrial cancer: Analysis of post-relapse survival by pattern of recurrence and secondary treatment. Int. J. Gynecol. Cancer 2020, 30, 193–200. [Google Scholar] [CrossRef]
- Creutzberg, C.L.; van Putten, W.L.; Koper, P.C.; Lybeert, M.L.; Jobsen, J.J.; Wárlám-Rodenhuis, C.C.; De Winter, K.A.; Lutgens, L.C.; van der Bergh, A.C.; van der Steen-Banasik, E.; et al. Survival after relapse in patients with endometrial cancer: Results from a randomized trial. Gynecol. Oncol. 2003, 89, 201–209. [Google Scholar] [CrossRef]
- Young, M.; Higgins, S.A.; Ratner, E.; Yu, J.; Mani, S.; Silasi, D.-A.; Azodi, M.; Rutherford, T.; Schwartz, P.E.; Damast, S. Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer. Int. J. Gynecol. Cancer 2015, 25, 431–439. [Google Scholar] [CrossRef]
- Hardarson, H.A.; Heidemann, L.N.; Christensen, R.D.; Mogensen, O.; Jochumsen, K.M. Vaginal vault recurrences of endometrial cancer in non-irradiated patients—Radiotherapy or surgery. Gynecol. Oncol. Rep. 2015, 11, 26–30. [Google Scholar] [CrossRef]
- Baek, S.; Isohashi, F.; Yamaguchi, H.; Mabuchi, S.; Yoshida, K.; Kotsuma, T.; Yamazaki, H.; Tanaka, E.; Sumida, I.; Tamari, K.; et al. Salvage high-dose-rate brachytherapy for isolated vaginal recurrence of endometrial cancer. Brachytherapy 2016, 15, 812–816. [Google Scholar] [CrossRef]
- Yanazume, S.; Arimura, T.; Kobayashi, H.; Douchi, T. Potential proton beam therapy for recurrent endometrial cancer in the vagina. J. Obstet. Gynaecol. Res. 2015, 41, 813–816. [Google Scholar] [CrossRef] [PubMed]
- Schmidt, A.-M.; Imesch, P.; Fink, D.; Egger, H. Pelvic Exenterations for Advanced and Recurrent Endometrial Cancer: Clinical Outcomes of 40 Patients. Int. J. Gynecol. Cancer 2016, 26, 716–721. [Google Scholar] [CrossRef] [PubMed]
- Chiantera, V.; Rossi, M.; De Iaco, P.; Koehler, C.; Marnitz, S.; Gallotta, V.; Margariti, P.A.; Parazzini, F.; Scambia, G.; Schneider, A.; et al. Pelvic Exenteration for Recurrent Endometrial Adenocarcinoma: A Retrospective Multi-institutional Study About 21 Patients. Int. J. Gynecol. Cancer 2014, 24, 880–884. [Google Scholar] [CrossRef] [PubMed]
- Margolis, B.; Kim, S.W.; Chi, D.S. Long-term survival after anterior pelvic exenteration and total vaginectomy for recurrent endometrial carcinoma with metastatic inguinal nodes at the time of surgery. Gynecol. Oncol. Rep. 2016, 19, 39–41. [Google Scholar] [CrossRef]
- Smaniotto, D.; D’Agostino, G.; Luzi, S.; Valentini, V.; Macchia, G.; Mangiacotti, M.G.; Margariti, P.A.; Ferrandina, G.; Scambia, G. Concurrent 5-Fluorouracil, Mitomycin C and Radiation, with or without Brachytherapy, in Recurrent Endometrial Cancer: A Scoring System to Predict Clinical Response and Outcome. Tumori J. 2005, 91, 215–220. [Google Scholar] [CrossRef]
- Huang, K.; D’Souza, D.; Patil, N.; Velker, V.; Leung, E.; Stitt, L.; Whiston, F.; Sugimoto, A.; McGee, J.; Prefontaine, M. High-dose-rate interstitial brachytherapy for the treatment of high-volume locally recurrent endometrial carcinoma. Brachytherapy 2016, 15, 543–548. [Google Scholar] [CrossRef]
- Kamran, S.C.; Manuel, M.M.; Catalano, P.; Cho, L.; Damato, A.L.; Lee, L.J.; Schmidt, E.J.; Viswanathan, A.N. MR- versus CT-based high-dose-rate interstitial brachytherapy for vaginal recurrence of endometrial cancer. Brachytherapy 2017, 16, 1159–1168. [Google Scholar] [CrossRef]
- Pierga, J.-Y.; Diéras, V.; Beuzeboc, P.; Dorval, T.; Palangié, T.; Jouve, M.; Scholl, S.; Garcia-Giralt, E.; Pouillart, P. Phase II Trial of Doxorubicin, 5-Fluorouracil, Etoposide, and Cisplatin in Advanced or Recurrent Endometrial Carcinoma. Gynecol. Oncol. 1997, 66, 246–249. [Google Scholar] [CrossRef]
- Moore, T.D.; Phillips, P.H.; Nerenstone, S.R.; Cheson, B.D. Systemic treatment of advanced and recurrent endometrial carcinoma: Current status and future directions. J. Clin. Oncol. 1991, 9, 1071–1088. [Google Scholar] [CrossRef]
- Thigpen, J.T.; Brady, M.F.; Homesley, H.D.; Malfetano, J.; DuBeshter, B.; Burger, R.A.; Liao, S. Phase III Trial of Doxorubicin With or Without Cisplatin in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. J. Clin. Oncol. 2004, 22, 3902–3908. [Google Scholar] [CrossRef]
- Aapro, M.S.; van Wijk, F.H.; Bolis, G.; Chevallier, B.; van der Burg, M.E.L.; Poveda, A.; de Oliveira, C.F.; Tumolo, S.; di Palumbo, V.S.; Piccart, M.; et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann. Oncol. 2003, 14, 441–448. [Google Scholar] [CrossRef] [PubMed]
- Maani, E.V.; Maani, C.V. Radiation Therapy. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2022. [Google Scholar]
- Fayed, A.; Mutch, D.G.; Rader, J.S.; Gibb, R.K.; Powell, M.A.; Wright, J.D.; ElNaqa, I.; Zoberi, I.; Grigsby, P.W. Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67, 480–484. [Google Scholar] [CrossRef] [PubMed]
- Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann. Intern. Med. 2009, 151, 264–269. [Google Scholar] [CrossRef] [PubMed]
- Clavien, P.A.; Barkun, J.; de Oliveira, M.L.; Vauthey, J.N.; Dindo, D.; Schulick, R.D.; de Santibañes, E.; Pekolj, J.; Slankamenac, K.; Bassi, C.; et al. The Clavien-Dindo Classification of Surgical Complications: Five-year experience. Ann. Surg. 2009, 250, 187–196. [Google Scholar] [CrossRef] [PubMed]
- Pirtoli, L.; Ciatto, S.; Cionini, L.; Taddei, G.; Colafranceschi, M. Salvage with Radiotherapy of Postsurgical Relapses of Endometrial Cancer. Tumori J. 1980, 66, 475–480. [Google Scholar] [CrossRef]
- Kuten, A.; Grigsby, P.W.; Perez, C.A.; Fineberg, B.; Garcia, D.M.; Simpson, J.R. Results of radiotherapy in recurrent endometrial carcinoma: A retrospective analysis of 51 patients. Int. J. Radiat. Oncol. Biol. Phys. 1989, 17, 29–34. [Google Scholar] [CrossRef]
- Sears, J.D.; Greven, K.M.; Hoen, H.M.; Randall, M.E. Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer. Cancer 1994, 74, 1303–1308. [Google Scholar] [CrossRef]
- Nag, S.; Martínez-Monge, R.; Copeland, L.J.; Vacarello, L.; Lewandowski, G.S. Perineal Template Interstitial Brachytherapy Salvage for Recurrent Endometrial Adenocarcinoma Metastatic to the Vagina. Gynecol. Oncol. 1997, 66, 16–19. [Google Scholar] [CrossRef]
- Wylie, J.; Irwin, C.; Pintilie, M.; Levin, W.; Manchul, L.; Milosevic, M.; Fyles, A. Results of Radical Radiotherapy for Recurrent Endometrial Cancer. Gynecol. Oncol. 2000, 77, 66–72. [Google Scholar] [CrossRef]
- Petignat, P.; Jolicoeur, M.; Alobaid, A.; Drouin, P.; Gauthier, P.; Provencher, D.; Donath, D.; Van Nguyen, T. Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial cancer recurrence. Gynecol. Oncol. 2006, 101, 445–449. [Google Scholar] [CrossRef]
- Huh, W.K.; Straughn, J.M., Jr.; Mariani, A.; Podratz, K.C.; Havrilesky, L.J.; Alvarez-Secord, A.; Gold, M.A.; McMeekin, D.S.; Modesitt, S.; Cooper, A.L.; et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: A multiinstitutional experience. Int. J. Gynecol. Cancer 2007, 17, 886–889. [Google Scholar] [CrossRef] [PubMed]
- Attarian, H.; Rezvani, H.; GHadyani, M.; Attarian, S.; Okhovatian, A.; Khosravi, A. Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer. Int. J. Hematol. Oncol. Stem. Cell Res. 2009, 3, 1–3. [Google Scholar]
- Leslie, K.K.; Sill, M.W.; Fischer, E.; Darcy, K.M.; Mannel, R.S.; Tewari, K.S.; Hanjani, P.; Wilken, J.A.; Baron, A.T.; Godwin, A.K.; et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study. Gynecol. Oncol. 2013, 129, 486–494. [Google Scholar] [CrossRef]
- Vance, S.; Burmeister, C.; Rasool, N.; Buekers, T.; Elshaikh, M.A. Salvage Versus Adjuvant Radiation Treatment for Women With Early-Stage Endometrial Carcinoma: A Matched Analysis. Int. J. Gynecol. Cancer 2016, 26, 307–312. [Google Scholar] [CrossRef] [PubMed]
- Chapman, C.H.; Maghsoudi, K.; Littell, R.D.; Chen, L.-M.; Hsu, I.-C. Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy. Brachytherapy 2017, 16, 1152–1158. [Google Scholar] [CrossRef] [PubMed]
- Francis, S.R.; Ager, B.J.; Do, O.A.; Huang, Y.-H.J.; Soisson, A.P.; Dodson, M.K.; Werner, T.L.; Sause, W.T.; Grant, J.D.; Gaffney, D.K. Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy. Gynecol. Oncol. 2019, 154, 38–44. [Google Scholar] [CrossRef]
- Crosbie, E.J.; Kitson, S.J.; McAlpine, J.N.; Mukhopadhyay, A.; Powell, M.E.; Singh, N. Endometrial cancer. Lancet 2022, 399, 1412–1428. [Google Scholar] [CrossRef]
- Kao, M.-S. Management of recurrent endometrial carcinoma. Chang Gung Med. J. 2004, 27, 639–645. [Google Scholar]
- Laban, M.; El-Swaify, S.T.; Ali, S.H.; Refaat, M.A.; Sabbour, M.; Farrag, N.; Hassanin, A.S. The Prediction of Recurrence in Low-Risk Endometrial Cancer: Is It Time for a Paradigm Shift in Adjuvant Therapy? Reprod. Sci. 2022, 29, 1068–1085. [Google Scholar] [CrossRef]
- Ronsini, C.; Köhler, C.; De Franciscis, P.; La Verde, M.; Mosca, L.; Solazzo, M.C.; Colacurci, N. Laparo-assisted vaginal radical hysterectomy as a safe option for Minimal Invasive Surgery in early stage cervical cancer: A systematic review and meta-analysis [published correction appears in Gynecol Oncol. Gynecol. Oncol. 2022, 166, 188–195. [Google Scholar] [CrossRef]
- Siegenthaler, F.; Lindemann, K.; Epstein, E.; Rau, T.; Nastic, D.; Ghaderi, M.; Rydberg, F.; Mueller, M.; Carlson, J.; Imboden, S. Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification. Gynecol. Oncol. 2022, 165, 230–238. [Google Scholar] [CrossRef] [PubMed]
- Raffone, A.; Travaglino, A.; Raimondo, D.; Neola, D.; Maletta, M.; Santoro, A.; Insabato, L.; Casadio, P.; Fanfani, F.; Zannoni, G.F.; et al. Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature. Gynecol. Oncol. 2022, 165, 192–197. [Google Scholar] [CrossRef] [PubMed]
- Restaino, S.; Tortorella, L.; Dinoi, G.; Zannoni, G.-F.; Baroni, A.; Capasso, I.; Distefano, E.; Sozzi, G.; Chiantera, V.; Scambia, G.; et al. Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: Prognostic and clinical implications. Eur. J. Cancer 2021, 142, 29–37. [Google Scholar] [CrossRef] [PubMed]
- Restaino, S.; Ronsini, C.; Finelli, A.; Perrone, E.; Scambia, G.; Fanfani, F. Role of blue dye for sentinel lymph node detection in early endometrial cancer. Gynecol. Surg. 2017, 14, 23. [Google Scholar] [CrossRef]
- Alletti, S.G.; Restaino, S.; Finelli, A.; Ronsini, C.; Lucidi, A.; Scambia, G.; Fanfani, F. Step by Step Total Laparoscopic Hysterectomy with Uterine Arteries Ligation at the Origin. J. Minim. Invasive Gynecol. 2020, 27, 22–23. [Google Scholar] [CrossRef]
- Fanfani, F.; Monterossi, G.; Di Meo, M.L.; La Fera, E.; Dell’Orto, F.; Gioè, A.; Lamanna, M.; Ferrari, D.; De Ponti, E.; Perego, P.; et al. Standard ultra-staging compared to one-step nucleic acid amplification for the detection of sentinel lymph node metastasis in endometrial cancer patients: A retrospective cohort comparison. Int. J. Gynecol. Cancer 2020, 30, 372–377. [Google Scholar] [CrossRef]
- Bradford, L.S.; Rauh-Hain, J.A.; Schorge, J.; Birrer, M.J.; Dizon, D.S. Advances in the Management of Recurrent Endometrial Cancer. Am. J. Clin. Oncol. 2015, 38, 206–212. [Google Scholar] [CrossRef]
- Zhu, L.; Le, T.; Popkin, D.; Olatunbosun, O. Quality-of-life analysis in the management of endometrial cancer. Am. J. Obstet. Gynecol. 2005, 192, 1388–1390. [Google Scholar] [CrossRef]
- Morice, P.; Leary, A.; Creutzberg, C.; Abu-Rustum, N.; Darai, E. Endometrial cancer. Lancet 2016, 387, 1094–1108. [Google Scholar] [CrossRef]
- Curran, W.J.; Whittington, R.; Peters, A.J.; Fanning, J. Vaginal recurrences of endometrial carcinoma: The prognostic value of staging by a primary vaginal carcinoma system. Int. J. Radiat. Oncol. Biol. Phys. 1988, 15, 803–808. [Google Scholar] [CrossRef]
- Greven, K.; Olds, W. Isolated vaginal recurrences of endometrial adenocarcinoma and their management. Cancer 1987, 60, 419–421. [Google Scholar] [CrossRef] [PubMed]
- Bristow, R.E.; Purinton, S.C.; Santillan, A.; Diaz-Montes, T.P.; Gardner, G.J.; Giuntoli, R.L., II. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol. Oncol. 2006, 103, 709–713. [Google Scholar] [CrossRef] [PubMed]
- Fung-Kee-Fung, M.; Dodge, J.; Elit, L.; Lukka, H.; Chambers, A.; Oliver, T. Follow-up after primary therapy for endometrial cancer: A systematic review. Gynecol. Oncol. 2006, 101, 520–529. [Google Scholar] [CrossRef] [PubMed]
- Lajer, H.; Elnegaard, S.; Christensen, R.D.; Ortoft, G.; Schledermann, D.E.; Mogensen, O. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey. Acta Obstet. Gynecol. Scand. 2012, 91, 97. [Google Scholar] [CrossRef]
Name | Country | Study Design | Period of Enrollment | FIGO Stage | No. of Participants | Treatment (Median Dose) | Mean FU * Months |
---|---|---|---|---|---|---|---|
Pirtoli 1980 ^ [26] | Italy | Retrospective observational monocenter study | 1960–1974 | - | 43 | External beam radiation therapy 4500–6000 rad in 5–6 weeks + boost dose 2000–3000 rad to vaginal vault | 60 |
Kuten 1989 [27] | USA | Retrospective observational monocenter study | 1959–1986 | I–IV | 51 | Preoperative and/or postoperative external beam radiation therapy 3978 cGy and/or brachytherapy 3000 cGy | 54 |
Sears 1994 [28] | USA | Prospective interventional monocenter study | 1973–1991 | I–IV | 45 | External beam radiation therapy 5000 cGy and/or brachytherapy 4000 cGy | 89 |
Nag 1997 [29] | USA | Prospective interventional monocenter study | 1989–1995 | - | 14 | External beam radiation therapy 4500–5000 cGy and/or brachytherapy 3000 cGy | 47 |
Pierga 1997 ^ [18] | France | Prospective interventional monocenter study | 1992–1996 | - | 6 | Doxorubicin, 5-fluorouracil, etoposide, and cisplatin | 30 |
Wylie 2000 [30] | Canada | Prospective interventional monocenter study | 1984–1988 | I–II | 58 | External beam radiation therapy 8150 cGy | 102 |
Smaniotto 2005 [15] | Italy | Prospective interventional monocenter study | 1992–2003 | - | 30 | 5-fluorouracil, mitomycin C, external beam radiation therapy 4-week split course: 2340 + 2340 cGy and/or brachytherapy 2000–2500 cGy | 27 |
Petignat 2006 [31] | Canada | Prospective interventional monocenter study | 1997–2003 | IB–IC | 22 | High-dose-rate interstitial brachytherapy 2600 cGy | 32 |
Huh 2007 [32] | USA | Prospective interventional multicenter study | 1975–2002 | IA–IB–IC | 69 | External beam radiation therapy and/or brachytherapy | 63 |
Attarian 2009 ^ [33] | Iran | Prospective interventional monocenter study | 2004–2007 | - | 11 | Carboplatin and Paclitaxel | 30 |
Leslie 2013 [34] | USA | Prospective interventional monocenter study | - | - | 30 | Lapatinib | - |
Vance 2016 ^ [35] | USA | Prospective interventional monocenter study | 1989–2013 | I–II | 39 | External beam radiation therapy 5470 cGy and/or brachytherapy 9430 cGy | 56 |
Chapman 2017 [36] | USA | Prospective interventional monocenter study | 2000–2010 | I–III | 30 | Salvage high-dose-rate brachytherapy 6830 cGy and external beam radiation therapy in 1.8 Gy daily fractions to a total of 4500 or 5040 cGy | 76 |
Kamran 2017 ^ [17] | USA | Retrospective case–control multicenter study | 2005–2016 | I–IV | 66 | High-dose-rate interstitial brachytherapy 7400 cGy | 33 |
Francis 2019 ^ [37] | USA | Prospective interventional multicenter study | 2000–2016 | I–II | 2691 | Salvage external beam radiation therapy 4500 cGy | 74 |
Name | 3Y DFS * (%) | 3Y OS ° (%) | 4.5Y DFS * (%) | 4.5Y OS ° (%) | Recurrence Rate (%) |
---|---|---|---|---|---|
Pirtoli 1980 ^ [26] | - | 21.0 | - | 16.0 | - |
Kuten 1989 [27] | 40.0 | 67.5 | 40.0 | 18.0 | 76.4 |
Sears 1994 [28] | - | - | 54.0 | 51.0 | 23.0 |
Nag 1997 [29] | - | - | 85.8 | 67.5 | 30.7 |
Pierga 1997 ^ [18] | 16.6 | 50.0 | - | - | - |
Wylie 2000 [30] | 69.0 | 62.5 | 68.0 | 53.0 | 98.2 |
Smaniotto 2005 [15] | 35.2 | 46.8 | - | - | 10.0 |
Petignat 2006 [31] | - | - | 96.0 | 96.0 | 4.5 |
Huh 2007 [32] | - | - | 83.0 | 75.0 | 17.0 |
Attarian 2009 ^ [33] | - | 80.0 | 36.3 | 27.2 | 54.0 |
Leslie 2013 [34] | - | - | - | - | - |
Vance 2016 ^ [35] | - | - | 77.0 | 72.0 | 23.0 |
Chapman 2017 [36] | 86.0 | 80.0 | 86.0 | 77.0 | 14.0 |
Kamran 2017 ^ [17] | 69.0 | 63.0 | - | - | 62.0 |
Francis 2019 ^ [37] | - | 73.0 | 100 | 65.0 | 3.7 |
Name | Site | Local Recurrence (%) | Distant Recurrence (%) | Mixed Recurrence (%) |
---|---|---|---|---|
Pirtoli 1980 ^ [26] | - | - | - | - |
Kuten 1989 [27] | Pelvis | 13.7 | 0.0 | 0.0 |
Sears 1994 [28] | - | - | - | - |
Nag 1997 [29] | Para-aortic nodes Lung Liver | 0.0 | 35.7 | 0.0 |
Pierga 1997 ^ [18] | - | - | - | - |
Wylie 2000 [30] | Vagina Pelvis | 6.8 | 0.0 | 0.0 |
Smaniotto 2005 [15] | - | - | - | - |
Petignat 2006 [31] | Para-aortic nodes Bone | 0.0 | 4.5 | 0.0 |
Huh 2007 [32] | - | - | - | - |
Attarian 2009 ^ [33] | - | - | - | - |
Leslie 2013 [34] | - | - | - | - |
Vance 2016 ^ [35] | - | - | - | - |
Chapman 2017 [36] | - | - | - | - |
Kamran 2017 ^ [17] | Iliac, inguinal, hilar, para-aortic nodes Mediastinum Peritoneal Perihepatic, presacral, prevertebral Lung Bone (L4 vertebra) Abdominal and left pelvic sidewall Vagina | 10.6 | 21.2 | 4.5 |
Francis 2019 ^ [37] | - | - | - | - |
Name | Complications (%) |
---|---|
Pirtoli 1980 ^ [26] | - |
Kuten 1989 [27] | 11.7 |
Sears 1994 [28] | - |
Nag 1997 [29] | 14.2 |
Pierga 1997 ^ [18] | 0.0 |
Wylie 2000 [30] | - |
Smaniotto 2005 [15] | 13.3 |
Petignat 2006 [31] | 68.1 |
Huh 2007 [32] | 5.0 |
Attarian 2009 ^ [33] | 0.0 |
Leslie 2013 [34] | 46.6 |
Vance 2016 [35] ^ | - |
Chapman 2017 [36] | - |
Kamran 2017 ^ [17] | 34.0 |
Francis 2019 ^ [37] | - |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ronsini, C.; Iavarone, I.; Reino, A.; Vastarella, M.G.; De Franciscis, P.; Sangiovanni, A.; Della Corte, L. Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review. J. Pers. Med. 2023, 13, 886. https://doi.org/10.3390/jpm13060886
Ronsini C, Iavarone I, Reino A, Vastarella MG, De Franciscis P, Sangiovanni A, Della Corte L. Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review. Journal of Personalized Medicine. 2023; 13(6):886. https://doi.org/10.3390/jpm13060886
Chicago/Turabian StyleRonsini, Carlo, Irene Iavarone, Antonella Reino, Maria Giovanna Vastarella, Pasquale De Franciscis, Angelo Sangiovanni, and Luigi Della Corte. 2023. "Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review" Journal of Personalized Medicine 13, no. 6: 886. https://doi.org/10.3390/jpm13060886